ROSWELL PARK CANCER INSTITUTE

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Single-Fraction SBRT Versus Standard Palliative Radiation Therapy in Treating Patients With Metastatic Cancer

Phase 2

Recruiting

Conditions: Metastatic Malignant Neoplasm

Interventions: Radiation: Palliative Radiation Therapy
Other: Quality-of-Life Assessment
Radiation: Stereotactic Body Radiation Therapy
Other: Questionnaire Administration

First Posted Date: 2019-08-28

Last Posted Date: 2024-04-25

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 1500

Registration Number: NCT04068649

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
🇺🇸
The Cancer Institute at St. Francis Hospital, East Hills, New York, United States
🇺🇸
Good Samaritan Hospital, West Islip, New York, United States

Respiratory Muscle Training Before Surgery in Preventing Lung Complications in Patients With Stage I-IIIB Lung Cancer

Phase 2

Recruiting

Conditions: Stage IA2 Lung Cancer AJCC v8
Stage II Lung Cancer AJCC v8
Stage IB Lung Cancer AJCC v8
Stage IIIA Lung Cancer AJCC v8
Stage IIIB Lung Cancer AJCC v8
Stage IA1 Lung Cancer AJCC v8
Stage IA3 Lung Cancer AJCC v8
Stage IIB Lung Cancer AJCC v8
Stage I Lung Cancer AJCC v8
Stage IIA Lung Cancer AJCC v8

Interventions: Other: Best Practice
Procedure: Laparoscopic Surgery
Other: Quality-of-Life Assessment
Other: Questionnaire Administration
Procedure: Video-Assisted Thoracic Surgery
Device: Respiratory Muscle Training Device

First Posted Date: 2019-08-28

Last Posted Date: 2024-08-02

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 220

Registration Number: NCT04067830

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Effects of Filter Ventilation on Sensory Response, Smoking Topography, and Inhalation in Current Every Day Cigarette Smokers

Completed

Conditions: Current Every Day Smoker
Cigarette Smoker

Interventions: Device: Medical Device
Other: Questionnaire Administration
Behavioral: Tobacco Smoking

First Posted Date: 2019-08-19

Last Posted Date: 2022-07-15

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 8

Registration Number: NCT04060446

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Pembrolizumab Every 12 Weeks Versus Every 3 Weeks in Treating Patients With Non-small Cell Lung Cancer

Phase 2

Active, not recruiting

Conditions: Lung Non-Small Cell Carcinoma

Interventions: Biological: Pembrolizumab

First Posted Date: 2019-07-25

Last Posted Date: 2024-04-26

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 9

Registration Number: NCT04032418

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Palliative Management of Inoperable Malignant Bowel Obstruction

Phase 2

Terminated

Conditions: Malignant Bowel Obstruction

Interventions: Drug: Dexamethasone
Drug: Metoclopramide
Drug: Octreotide

First Posted Date: 2019-07-22

Last Posted Date: 2022-11-29

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 15

Registration Number: NCT04027348

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Impact of Early Mobility on Post-Surgery Recovery in Patients Undergoing Oncologic Surgeries

Not Applicable

Terminated

Conditions: Malignant Neoplasm

Interventions: Other: Best Practice
Other: Physical Activity
Other: Questionnaire Administration

First Posted Date: 2019-06-27

Last Posted Date: 2022-07-22

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 17

Registration Number: NCT04000581

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Pulmonary Suffusion in Controlling Minimal Residual Disease in Patients With Sarcoma or Colorectal Metastases

Phase 1

Recruiting

Conditions: Metastatic Bone Sarcoma
Metastatic Unresectable Sarcoma
Resectable Sarcoma
Metastatic Malignant Neoplasm in the Lung
Metastatic Soft Tissue Sarcoma
Colorectal Cancer

Interventions: Drug: Cisplatin
Procedure: Isolated Chemotherapeutic Lung Perfusion
Procedure: Metastasectomy

First Posted Date: 2019-05-28

Last Posted Date: 2024-03-13

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 99

Registration Number: NCT03965234

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Adoptive Cell Therapy With (LN-145) in Combination With Pembrolizumab in Treating Patients With Unresectable or Metastatic Transitional Cell Cancer Who Have Failed Cisplatin-Based Chemotherapy

Phase 2

Withdrawn

Conditions: Metastatic Renal Pelvis Urothelial Carcinoma
Metastatic Ureter Urothelial Carcinoma
Metastatic Urethral Urothelial Carcinoma
Metastatic Bladder Urothelial Carcinoma
Unresectable Renal Pelvis Urothelial Carcinoma
Unresectable Ureter Urothelial Carcinoma

Interventions: Drug: Cyclophosphamide
Drug: Fludarabine
Drug: Fludarabine Phosphate
Biological: Pembrolizumab
Biological: Autologous Tumor Infiltrating Lymphocytes LN-145
Biological: Aldesleukin

First Posted Date: 2019-05-02

Last Posted Date: 2020-01-02

Lead Sponsor: Roswell Park Cancer Institute

Registration Number: NCT03935347

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Denosumab in Treating Patients With Bone Loss Due to Donor Stem Cell Transplant

Phase 2

Completed

Conditions: Allogeneic Hematopoietic Stem Cell Transplantation Recipient
Osteoporosis
Osteopenia

Interventions: Biological: Denosumab

First Posted Date: 2019-04-24

Last Posted Date: 2024-03-13

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 30

Registration Number: NCT03925532

Locations: 🇺🇸
Cleveland Clinic, Cleveland, Ohio, United States
🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Aspirin and Rintatolimod With or Without Interferon-alpha 2b in Treating Patients With Prostate Cancer Before Surgery

Phase 2

Suspended

Conditions: Prostate Adenocarcinoma
Stage II Prostate Cancer AJCC v8
Stage IIA Prostate Cancer AJCC v8
Stage IIIA Prostate Cancer AJCC v8
Stage IIIC Prostate Cancer AJCC v8
Stage I Prostate Cancer AJCC v8
Stage IIC Prostate Cancer AJCC v8
Stage IIB Prostate Cancer AJCC v8
Stage III Prostate Cancer AJCC v8
Stage IIIB Prostate Cancer AJCC v8

Interventions: Drug: Aspirin
Procedure: Radical Prostatectomy
Biological: Recombinant Interferon Alfa-2b
Drug: Rintatolimod

First Posted Date: 2019-04-02

Last Posted Date: 2024-07-11

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 30

Registration Number: NCT03899987

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy